PRESS RELEASE published on 05/14/2025 at 07:30, 1 year 1 month ago Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Nicox announces positive results of Whistler Phase 3b glaucoma trial with NCX 470 showing efficacy in lowering intraocular pressure via dual mechanism action of nitric oxide and prostaglandin analogs. Safety profile consistent with previous trial Nicox NCX 470 Glaucoma Trial Whistler Phase 3b Intraocular Pressure
BRIEF published on 04/30/2025 at 07:35, 1 year 1 month ago Nicox Reports Full Year 2024 Financials Net Loss Cash Reserves Nicox Financial Results VYZULTA Revenue Sale NCX 470 Trials
BRIEF published on 04/30/2025 at 07:35, 1 year 1 month ago Nicox publie ses résultats financiers pour l'année 2024 Perte Nette Réserves De Trésorerie Résultats Financiers De Nicox Vente De Revenus De VYZULTA Essais NCX 470
PRESS RELEASE published on 04/30/2025 at 07:30, 1 year 1 month ago Nicox Provides Full Year 2024 Financial Results Nicox reports €7.9 million revenue for 2024 with exceptional income of €13.7 million from VYZULTA transfer. Cash of €10.5 million and NCX 470 Phase 3 trial results expected in Q3 2025 Financial Results Revenue Nicox NCX 470 VYZULTA
PRESS RELEASE published on 04/30/2025 at 07:30, 1 year 1 month ago Nicox : Résultats financiers de l’année 2024 Nicox annonce résultats financiers 2024, incluant CA de 7,9M€, produits exceptionnels de 13,7M€ et trésorerie de 10,5M€. Études cliniques NCX 470 en cours Résultats Financiers Trésorerie Études Cliniques Nicox NCX 470
BRIEF published on 03/19/2025 at 07:35, 1 year 3 months ago Nicox Completes Final Visit for NCX 470 Phase 3b Whistler Glaucoma Trial Glaucoma Nicox Clinical Results NCX 470 Phase 3b Trial
BRIEF published on 03/19/2025 at 07:35, 1 year 3 months ago Nicox a terminé la dernière visite de l'essai de phase 3b NCX 470 sur le glaucome à Whistler Nicox Résultats Cliniques NCX 470 Glaucome Essai De Phase 3b
PRESS RELEASE published on 03/19/2025 at 07:30, 1 year 3 months ago Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Nicox completes final patient visits in Phase 3b Whistler Glaucoma Trial for NCX 470, with results expected May 2025. Denali trial in progress, results planned for Q3 2025 Clinical Development Nicox NCX 470 Phase 3b Glaucoma Trial
PRESS RELEASE published on 03/19/2025 at 07:30, 1 year 3 months ago Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Nicox annonce la fin de la visite du dernier patient dans l'étude de phase 3b Whistler sur le NCX 470 pour le glaucome. Résultats attendus en mai 2025 Étude Clinique Nicox NCX 470 Glaucome Phase 3b
BRIEF published on 01/28/2025 at 07:35, 1 year 4 months ago Nicox : Participation aux Grands Congrès en 2025 Investissement Ophtalmologie Congrès Nicox NCX 470
Published on 06/26/2026 at 01:40, 6 hours 58 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 9 hours 8 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 10 hours 8 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 11 hours 6 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 17 hours 8 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 08:00, 38 minutes ago MHM Corporate: Debt Restructuring through Bonds Redeemable in Shares
Published on 06/26/2026 at 08:00, 38 minutes ago MHM Corporate: Restructuration de sa dette par voie d'obligations remboursables en actions
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago REINET INVESTMENTS S.C.A. ANNOUNCES REVISED DATE FOR ANNUAL GENERAL MEETING
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago THE NAGA GROUP AG CONFIRMS FY 2025 REVENUES AND REPORTS STRONGER-THAN-EXPECTED EBITDA
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago Pyrum Innovations AG reports results for the first three months of 2026
Published on 06/26/2026 at 07:00, 1 hour 38 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 1 hour 38 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 13 hours 53 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 14 hours 8 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 14 hours 48 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
